PITTSBURGH, March 22, 2011 /PRNewswire/ — Mylan Inc. (Nasdaq:
MYL) today announced that its subsidiary UDL Laboratories, part
of the Mylan Institutional business, has entered a license
agreement with Humeca, a leading plastic surgery and burn treatment
products company, for the exclusive U.S. distribution rights of
Humeca products. Humeca, which is based in the Netherlands, has a
portfolio that includes products used by burn, plastic and
reconstructive surgeons to repair skin defects.
Mylan Institutional President Matt Erick commented: “Mylan
Institutional is extremely pleased to have found a partner as
strong as Humeca to accelerate our growth in the burn and wound
care space. For the first time in the U.S., plastic and
reconstructive surgeons will have access to Humeca’s modified MEEK
micrografting system, the method of choice for skin
transplantation. The addition of Humeca’s innovative products to
UDL’s established line of advanced wound and burn care products
positions Mylan Institutional for growth in this sector.”
Humeca’s modified MEEK micrografting system greatly reduces the
donor surface area required for skin transplantation when compared
to the commonly-used mesh graft technique. This is especially
useful for treating patients with large burns who have limited
donor tissue availability.
UDL Laboratories is part of Mylan Institutional, a platform that
provides differentiated pharmaceutical products to institutional
customers throughout North America. Mylan Institutional’s product
offering includes the specialty injectables of Bioniche Pharma with
the unit dose capabilities of Mylan’s UDL Laboratories. Mylan
Institutional’s customers include group purchasing organizations,
wholesalers, hospitals, surgical and radiology services, home
infusion service providers, long-term care facilities, correctional
facilities, specialty pharmacies, veterinary clini
‘/>”/>
SOURCE
